newsNew data demonstrates the long-term safety and efficacy of Evrysdi®…
16 March 2022 | By Hannah Balfour (European Pharmaceutical Review)
New data demonstrates the long-term safety and efficacy of Evrysdi® (risdiplam) in a broad population of people with spinal muscular atrophy (SMA).
